Search peptides, terms, sources/
Growth hormone axis

Sermorelin

Also known as: Sermorelin acetate · GRFNH2 · GHRH-NH2

Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

3 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Sermorelin is recorded as not licensed in the UK (checked 14 August 2026).

Best study type
Human trials2 human trials

What is Sermorelin?

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone that stimulates growth hormone release, studied in children with growth hormone deficiency and, in small older trials, in adults. It is not licensed in the UK, and the evidence is mainly a narrative review and small trials from before 2000.

It is a 29-amino-acid fragment that acts on the GHRH receptor in the pituitary gland. The US FDA approved it in the 1990s for diagnostic testing and for treating growth hormone deficiency in children.

Class
GHRH Analogue (Growth Hormone Secretagogue)
Origin
Fragment / derived
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Sermorelin work?

Sermorelin copies the first 29 amino acids of growth-hormone-releasing hormone. It binds receptors on the pituitary gland, which then releases the body's own growth hormone. The body's normal feedback still applies, so release stays self-limiting, unlike with growth hormone itself.

The mechanism in more detail

Sermorelin binds GHRH receptors on somatotroph cells in the anterior pituitary, activating cAMP-dependent signalling that upregulates growth hormone gene transcription and promotes release of stored growth hormone. Unlike exogenous growth hormone itself, sermorelin’s effect remains subject to the body’s normal negative-feedback control via hypothalamic somatostatin, meaning the pituitary retains regulatory control over total GH output and the normal pulsatile secretion pattern is preserved, according to the mechanistic literature reviewed.

Sermorelin’s regulatory history is unusually well-sourced for a peptide of this kind: it was approved by the US FDA for diagnostic GH-stimulation testing in 1990 and for treatment of paediatric growth hormone deficiency in 1997, and a 2013 US Federal Register determination confirmed that the approved product was not withdrawn from sale for reasons of safety or effectiveness. This regulatory record is better corroborated than sermorelin’s published efficacy evidence, which is comparatively thin: the clinical trials examining sermorelin in adults and in age-related contexts are small, decades old, and have not been independently replicated in more recent research. Two such trials in older adults reached different conclusions on whether sermorelin produced measurable changes in body composition, and this inconsistency has not been resolved by any later, larger study identified in the sourced literature.

Mechanisms and targets

GHRH-Receptor AgonismPhysiologically-Regulated GH Secretagogue (Negative-Feedback-Preserving)Pituitary Somatotroph StimulationGHRH Receptor (GHRH-R)

Classification and structure

Names
Sermorelin; Sermorelin acetate; GRF(1-29)NH2; GHRH(1-29)-NH2; Geref (discontinued US brand name)
Class
GHRH Analogue (Growth Hormone Secretagogue)
Origin
Fragment / derived
Structure
A 29-amino-acid peptide corresponding to the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH 1-29), amidated at the C-terminus, described in the literature as the shortest synthetic peptide with full biological activity of GHRH.
Routes used in the research
Intravenous injection for the diagnostic growth hormone stimulation test (the historical FDA-approved use) and subcutaneous injection in the treatment and ageing-research trials.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Sermorelin has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
13001

1999 review, childhood GH deficiency Limited

A 1999 review of the diagnostic and treatment literature for sermorelin in children with idiopathic growth hormone deficiency concluded that intravenous sermorelin is a rapid, relatively specific provocative test for diagnosing growth hormone deficiency, with fewer false-positive responses in non-deficient children than other provocative tests, and that subcutaneous sermorelin is effective in promoting growth in some prepubertal children with idiopathic growth hormone deficiency, with sustained increases in height velocity over 12 months and catch-up growth maintained in a few children followed to 36 months.

Study type
Narrative review
Population
Prepubertal children with idiopathic growth hormone deficiency (pooled across the trials the 1999 review cites)
Source
1 Prakash et al., 1999

Limitation: A narrative literature review, not a systematic review.

Limitations in full

A narrative literature review, not a systematic review. The paediatric trials it pools have not been re-checked against the original papers. The evidence base dates from before 2000.

Geref US regulatory record Not graded

Sermorelin (Geref) received US FDA approval for diagnostic use, growth hormone stimulation testing, in December 1990, and subsequently for treatment of idiopathic growth hormone deficiency in children with growth failure in September 1997. The manufacturer discontinued the product in 2008, and a 2013 US Federal Register determination confirmed that Geref was not withdrawn from sale for reasons of safety or effectiveness.

Study type
Regulatory / legislative document
Population
Not applicable; regulatory record, not a clinical study
Source
2 Federal Register, 2013

Limitation: This is a US regulatory record and has no bearing on UK or EU licensing status, addressed separately in this page's Regulatory Status section; it should not be read as implying any UK approval, current or historical.

Eleven elderly men, six weeks Limited

In 11 healthy elderly men aged 64 to 76 given subcutaneous sermorelin for 6 weeks, 12-hour mean nocturnal growth hormone output nearly doubled versus baseline, but IGF-1 levels did not significantly increase over this short treatment period, and no significant changes in body composition were observed, though some improvement was seen on a subset of muscle-strength tests.

Study type
Human trial
Population
11 healthy men aged 64 to 76, Johns Hopkins University School of Medicine
Source
3 Vittone et al., 1997

Limitation: Very small sample; short duration (6 weeks); no control group described in the available summary; pre-2000 with no identified independent replication at this age-related endpoint.

Limitations in full

Very small sample; short duration (6 weeks); no control group described in the available summary; pre-2000 with no identified independent replication at this age-related endpoint. This finding and the trial below both address sermorelin in ageing but reach different conclusions on body composition; both are reported here rather than one being silently preferred.

Nineteen adults aged 55-71 Limited

In a single-blind, randomised, placebo-controlled trial of 19 men and women aged 55 to 71, following a 4-week placebo run-in and then 16 weeks of a subcutaneous sermorelin analogue, nocturnal growth hormone and IGF-1 levels increased significantly in both sexes. Men showed a mean lean-body-mass increase of 1.26 kg and improved insulin sensitivity; participants reported subjective improvements in general well-being and libido; skin thickness increased significantly.

Study type
Human trial
Population
19 men and women aged 55 to 71, University of California
Source
4 Khorram et al., 1997

Limitation: Single small trial; single-blind design, weaker than double-blind; data are from 1997, with no modern replication identified; well-being and libido outcomes are self-reported and not independently corroborated; results partly conflict with the elderly-men trial above on body-composition change.

Negative-feedback mechanism Preliminary

Sermorelin acts through the same physiological negative-feedback loop, hypothalamic somatostatin, as endogenous growth hormone-releasing hormone. Per mechanistic and narrative-review literature, its growth-hormone-releasing effect is self-limiting compared with exogenous growth hormone administration, and normal pulsatile growth hormone secretion patterns are retained.

Study type
Academic publication, Narrative review
Population
Mechanistic and narrative-review literature; not a single clinical population
Source
5 Sinha et al., 2020

Limitation: Narrative review, not primary pharmacological data.

Limitations in full

Narrative review, not primary pharmacological data. Correctly used for mechanism-of-action prose only, not as a graded efficacy or safety claim.

What safety findings have been reported?

3 safety findings are recorded for Sermorelin. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Federal Register withdrawal determination

A 2013 US Federal Register determination confirms that Geref (sermorelin) was not withdrawn from the US market for reasons of safety or effectiveness; the manufacturer discontinued it in 2008. The FDA record for the discontinued formulation was reviewed. It is a regulatory record, not a safety trial, and it does not describe the safety of any product sold in the UK.

Source
2 Federal Register, 2013

Adverse-event reporting, 11 men

11 older men were given sermorelin by injection for 6 weeks. No serious adverse events were reported in the available summary, which focused on growth hormone, IGF-1 and body composition rather than a formal adverse-event analysis. The trial was too small to rule out rarer harms.

Source
3 Vittone et al., 1997

Adverse-event reporting, 19 adults

19 older adults were given sermorelin for 16 weeks in a randomised controlled trial. No serious adverse events were reported in the available summary. The summary reports changes in well-being, libido, lean mass, insulin sensitivity and skin thickness, not adverse findings. The trial was too small to rule out rarer harms.

Source
4 Khorram et al., 1997

What is Sermorelin's UK regulatory status?

Marketing authorisation
No UK marketing authorisation was identified for sermorelin or sermorelin acetate, now or in the past. A search of EMA centralised authorisations found none. This is a search result, not a confirmed exhaustive absence.
Prescription status
Not applicable in the UK, there is no licensed UK product to classify. Any current UK supply would fall under the unlicensed medicine or specials-import framework (Human Medicines Regulations 2012, SI 2012/1916, Regulation 167) rather than a standard POM, P or GSL classification.
Medicine class
Not a licensed medicine in the UK. The only marketing authorisation sermorelin held was for Geref (US FDA, approved 1990 and 1997). The manufacturer discontinued the products in 2008, and in 2013 the FDA determined they were not withdrawn for reasons of safety or effectiveness. No UK or EU authorisation was identified.
MHRA position
Unlicensed in the UK. No evidence found of any UK Clinical Trial Authorisation activity for sermorelin in current public sources reviewed. Sermorelin sits in the same broad unlicensed category as other GH-secretagogues in this catalogue, but with a historically significant difference: sermorelin, uniquely among that peer group, once held a national marketing authorisation (US) that the manufacturer discontinued in 2008; the FDA determined this was not for reasons of safety or effectiveness.
Authorised use
None in the UK. Historically approved in the US only, for diagnostic testing of growth hormone deficiency and for treatment of idiopathic growth hormone deficiency in children with growth failure; both indications lapsed with the product's 2008 discontinuation.
Research use
No active UK clinical-trial programme has been identified.
Other restrictions
Not identified as a controlled substance under UK Misuse of Drugs legislation. No MHRA public safety notice naming sermorelin has been identified. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names sermorelin under S2.2.4, growth hormone-releasing hormone analogues.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Sermorelin is recorded as not licensed in the UK (checked 14 August 2026).

References

6 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Prakash A, Goa KL (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugsNarrative review · DOI 10.2165/00063030-199912020-00007 · PMID 18031173 · Original ↗
  2. US Food and Drug Administration (2013). Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register (US)Regulatory / legislative document · Original ↗
  3. Vittone J, Blackman MR, Busby-Whitehead J, et al. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism: Clinical and ExperimentalHuman clinical trial · DOI 10.1016/s0026-0495(97)90174-8 · PMID 9005976 · Original ↗
  4. Khorram O, Laughlin GA, Yen SSC (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology & MetabolismHuman clinical trial, RCT · PMID 9141536 · Original ↗
  5. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and UrologyNarrative review · PMID 32257855 · Original ↗
  6. MHRA Guidance on unlicensed medicinal products ("specials"), Guidance Note 14. GOV.UK / MHRARegulatory / legislative document · Original ↗

Questions about Sermorelin

What is Sermorelin?

Sermorelin is a synthetic fragment of growth-hormone-releasing hormone that stimulates growth hormone release, studied in children with growth hormone deficiency and, in small older trials, in adults. It is not licensed in the UK, and the evidence is mainly a narrative review and small trials from before 2000. Read what it is.

Is Sermorelin licensed in the UK?

PeptGuru records Sermorelin's UK status as: Not licensed in the UK. No UK marketing authorisation was identified for sermorelin or sermorelin acetate, now or in the past. UK status checked 14 August 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Sermorelin show?

PeptGuru records 5 research findings for Sermorelin: 2 from human trials and 3 from regulatory or other records. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Sermorelin?

3 safety findings are recorded, including: federal register withdrawal determination; adverse-event reporting, 11 men; adverse-event reporting, 19 adults. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Sermorelin?

All 6 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Correction · Removed an unsourced reason for the withdrawal of Geref. The FDA record says only that it was not withdrawn for safety or effectiveness reasons.
  • Regulatory update · WADA 2026 listing added (S2.2.4).

How findings are graded: the grading method. All changes.

  • GHRP-2Pralmorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-6Growth hormone-releasing…

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • HexarelinExamorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. In a long-term human study the response faded and IGF-I and body composition did not change.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK

Compare Sermorelin with GHRP-2

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.